Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning Ixazomib & Multiple Myeloma (MM) / Plasmocytoma, Ixazomib maintenance prolongs PFS with no unexpected toxicity in patients with newly diagnosed Multiple Myeloma (MM) / Plasmocytoma not undergoing ASCT (autologous stem cell transplantation). To our knowledge, this is the first Proteasome inhibitor demonstrated in a randomized clinical trial to have single-agent efficacy for maintenance and is the first oral Proteasome inhibitor option in this patient population.
In the clin…